HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

Panelists highlight that oral endocrine therapies for hormone receptor-positive breast cancer are generally well tolerated ...

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission (EC) for its new ...

Panelists discuss the rapidly evolving endocrine treatment landscape in oncology, emphasizing the shift toward personalized ...

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...

This study investigates the potential of amygdalin, a natural compound found in almonds, peaches, and apples, as a therapeutic agent for HER2-positive ...

CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an ...